<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942021000500026</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Toxoplasmosis ocular activa: consideraciones actuales sobre el tratamiento]]></article-title>
<article-title xml:lang="en"><![CDATA[Active ocular toxoplasmosis: current management considerations]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Naranjo Valladares]]></surname>
<given-names><![CDATA[Bárbara Taysel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[León Sánchez]]></surname>
<given-names><![CDATA[Maria Amparo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos López]]></surname>
<given-names><![CDATA[Meisy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río Centro Provincial Oftalmológico de Pinar del Río ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Pinar del Río Hermanos Saiz Montes de Oca  ]]></institution>
<addr-line><![CDATA[Pinar del Río ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Ciencias Médicas de la Habana Instituto Cubano de Oftalmología Ramón Pando Ferrer ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2021</year>
</pub-date>
<volume>25</volume>
<numero>5</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942021000500026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942021000500026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942021000500026&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: la toxoplasmosis ocular constituye la principal causa de uveítis posterior en el mundo; representa un trastorno recurrente con fatales consecuencias para la visión.  Objetivo:  exponer las diferentes alternativas actuales de tratamiento en la toxoplasmosis ocular  Métodos:  se llevó a cabo una búsqueda bibliográfica con el empleo de literatura nacional e internacional, en formato electrónico e impreso en el buscador de acceso libre Google académico y las bases de datos de Medline/Pubmed y Scielo.  Desarrollo:  en la actualidad aún no existe un consenso en cuanto a la mejor pauta de tratamiento, por lo que el objetivo de esta revisión es exponer las diferentes alternativas según la bibliografía consultada nacional e internacional. Sus indicaciones están determinadas por las condiciones clínicas del paciente: la edad pediátrica, el embarazo, el estado inmune del individuo enfermo, la intensidad del cuadro inflamatorio ocular y el número de recurrencias. Las opciones terapéuticas de modo general se realizan con inhibidores de dihidrofolato, sulfonamidas y esteroides.  Conclusiones:  la finalidad del tratamiento está enfocada en disminuir la replicación del parásito durante la etapa activa y minimizar el daño retinal, fundamentalmente en las lesiones que afecten la mácula. Por lo que resulta de interés el conocimiento de las distintas alternativas, a fin de lograr un buen resultado visual del paciente afecto por toxoplasmosis ocular y evitar la discapacidad visual o ceguera por esta parasitosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: ocular toxoplasmosis is the leading cause of posterior uveitis in the world; it represents a recurrent disorder with fatal consequences for vision.  Objective: to present the different current treatment alternatives in ocular toxoplasmosis.  Methods: a bibliographic search was carried out using national and international medical literature, in electronic and printed format in the open access search engine Google Scholar and the Medline/Pubmed and SciELO databases.  Development: at present there is still no consensus as to the best treatment guideline, therefore the aim of this review is to present the different alternatives according to the national and international medical literature consulted. Its indications are determined by the clinical conditions of the patient: pediatric age, pregnancy, the immune status of the patient, the intensity of the ocular inflammatory condition and the number of recurrences. The therapeutic options are generally carried out with dihydrofolate inhibitors, sulfonamides and steroids.  Conclusions: the purpose of treatment is focused on reducing parasite replication during the active stage and minimizing retinal damage, mainly in lesions affecting the macula. Therefore, it is of interest to know the different alternatives in order to achieve a good visual outcome in patients affected by ocular toxoplasmosis and avoid visual disability or blindness due to this parasitic disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[UVEÍTIS]]></kwd>
<kwd lng="es"><![CDATA[TOXOPLASMOSIS OCULAR]]></kwd>
<kwd lng="es"><![CDATA[TERAPÉUTICA]]></kwd>
<kwd lng="es"><![CDATA[ANTIINFECCIOSOS]]></kwd>
<kwd lng="es"><![CDATA[CORTICOESTEROIDES]]></kwd>
<kwd lng="en"><![CDATA[UVEITIS]]></kwd>
<kwd lng="en"><![CDATA[TOXOPLASMOSIS, OCULAR]]></kwd>
<kwd lng="en"><![CDATA[THERAPEUTIC]]></kwd>
<kwd lng="en"><![CDATA[ANTI-INFECTIVE AGENTS]]></kwd>
<kwd lng="en"><![CDATA[ADRENAL CORTEX HORMONES]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Vitale]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<source><![CDATA[Diagnosis and treatment of uveitis]]></source>
<year>2013</year>
<publisher-loc><![CDATA[London New York ]]></publisher-loc>
<publisher-name><![CDATA[Philadelphia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Camejo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Araujo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La toxoplasmosis observada como un problema no resuelto]]></article-title>
<source><![CDATA[Rev Cubana Invest Bioméd]]></source>
<year>2016</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>273-83</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>American Academy of Ophthalmology</collab>
<source><![CDATA[Basic and Clinical Science Course 2020-2021. Uveitis and ocular inflammation]]></source>
<year>2020</year>
<publisher-loc><![CDATA[San Francisco ]]></publisher-loc>
<publisher-name><![CDATA[American Academy of Ophthalmology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mokua Mose]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Maina Kagira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muchina Kamau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wangari Maina]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ngotho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Karanja]]></surname>
<given-names><![CDATA[Muturi]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["A Review on the Present Advances on Studies of Toxoplasmosis in Eastern Africa"]]></article-title>
<source><![CDATA[BioMed Research International]]></source>
<year>2020</year>
<numero>10</numero>
<issue>10</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Callizo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Valledeperas]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión de la prevención y tratamiento de la toxoplasmosis ocular]]></article-title>
<source><![CDATA[Annals d&#8217;Oftalmologia]]></source>
<year>2004</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estevão]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Veronese Rodrigues]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Dinis Costa]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bollela Valdes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency and visual outcomes of ocular toxoplasmosis in an adult Brazilian population]]></article-title>
<source><![CDATA[Scientific Reports]]></source>
<year>2021</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3420</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pantoja Ramos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez García]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reseña histórica acerca de las investigaciones relacionadas con la toxoplasmosis]]></article-title>
<source><![CDATA[Rev Cubana Med Trop]]></source>
<year>2001</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>111-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ashander]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Cordeiro]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Arruda]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Cordeiro]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Lie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis of ocular toxoplasmosis]]></article-title>
<source><![CDATA[Sciencedirect]]></source>
<year>2020</year>
<numero>81</numero>
<issue>81</issue>
<page-range>100882</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Facio Lince]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[López de Mesa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxoplasmosis ocular en Colombia: 10 años de aportes investigativos]]></article-title>
<source><![CDATA[Rev Soc Colomb Oftalmol]]></source>
<year>2018</year>
<volume>51</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-28</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozgonul]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Besirli]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis]]></article-title>
<source><![CDATA[Ophthalmic Res]]></source>
<year>2017</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandão-de-Resende]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Babu Balasundaram]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Narain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mahendradas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vascocelos-Santos]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multimodal Imaging in Ocular Toxoplasmosis]]></article-title>
<source><![CDATA[Ocul Immunol Inflamm]]></source>
<year>2020</year>
<volume>28</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1196-204</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrer Mellor]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sevilla Pérez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lacorzana]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo Mancheño]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[García Serrano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novedades para el diagnóstico de la toxoplasmosis ocular usos de la tomografía de coherencia óptica]]></article-title>
<source><![CDATA[Anales de pediatría]]></source>
<year>2020</year>
<volume>92</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garwed]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Pleyer]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treament Strategy in Human Ocular toxoplasmosis: Why antibiotics Have Failed]]></article-title>
<source><![CDATA[J. Clin Med]]></source>
<year>2021</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1090</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sameer]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Khars]]></surname>
<given-names><![CDATA[WI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ocular toxoplasmosis related macular traction: A case report and review of the literature]]></article-title>
<source><![CDATA[Saudi Journal of Ophthalmology]]></source>
<year>2019</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rio Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Argones]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Silva]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Oftalmología. Diagnóstico y tratamiento]]></source>
<year>2018</year>
<edition>2da</edition>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simsek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ozdal]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Kocer]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optic nerve involvement in ocular toxoplasmosis: 12 year data from a tertiary referral center in Turkey]]></article-title>
<source><![CDATA[Arq Bras Oftalmol]]></source>
<year>2019</year>
<volume>82</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>302-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kandwala]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Besirli]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<source><![CDATA[Ocular toxoplasmosis: a refrecher]]></source>
<year>2020</year>
<publisher-loc><![CDATA[San Francisco ]]></publisher-loc>
<publisher-name><![CDATA[American Academy of Ophthalmology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo Barbado]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado Martínez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Formulario nacional de medicamentos]]></source>
<year>2014</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soheilian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sadoughi]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Ghajarnia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Behboudi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Anisian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peyman]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2005</year>
<volume>112</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1876-82</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz Valle]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez Fernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Benítez del Castillo Sánchez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Actualización en el tratamiento de las uveítis]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Las Palmas de Gran Canaria ]]></publisher-loc>
<publisher-name><![CDATA[Mac Line S.L]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Opremcak]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Scales]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Sharpe]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trimethropim-sulfamethoxazole therapy for ocular toxoplasmosis]]></article-title>
<source><![CDATA[Ophthalmol]]></source>
<year>1992</year>
<volume>99</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>920-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunay]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Gajurel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dhakal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Liesenfeld]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice]]></article-title>
<source><![CDATA[Clin Microbiol Rev]]></source>
<year>2018</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e00057-17</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuluaga]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Castaño]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Hernando Donado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efecto del tratamiento prenatal con espiramicina en la frecuencia de retinocoroiditis por toxoplasmosis congénita en una cohorte colombiana]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2017</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jasper]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vedula]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Horo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sepah]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[QD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corticosteroids as adjuvant therapy for ocular toxoplasmosis]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2017</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shammaa]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Powel]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Benmerzouga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse outcomes associated with the treatment of Toxoplasma infections]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2021</year>
<volume>96</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1035</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soheilian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramezani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Azimzadeh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sadoughi]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Dehghan]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Shahghadami]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine and prednisolone treatment of ocular toxoplasmosis]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2011</year>
<volume>118</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>134-41</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lashay]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mirshahi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Parandin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Riazi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Masloumi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective randomized trial of azithromycin versus trimethropim-sulfamethoxazole in treatment of toxoplasmic retinochoroiditis]]></article-title>
<source><![CDATA[Journal of Current Ophthalmology]]></source>
<year>2017</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-5</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yates]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Chiong]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zagora]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wakefield]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McCluskey]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ocular Toxoplasmosis in a Tertiary Referral Center in Sydney Australia-Clinical Features, treatment, and Prognosis]]></article-title>
<source><![CDATA[Asia Pac J Ophthalmol (Phila)]]></source>
<year>2019</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>280-4</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casoy J Nascimento]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[LMP]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Zamora]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Muccioli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[JRO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of Treatments for Ocular Toxoplasmosis]]></article-title>
<source><![CDATA[Ocul Immunol Inflamm]]></source>
<year>2020</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>249-55</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos Gómez]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Tejeda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Baguer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Linares Guerra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno Arrieta]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxoplasmosis ocular y rehabilitación visual. Presentación de un caso]]></article-title>
<source><![CDATA[Rev haban cienc méd]]></source>
<year>2013</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-56</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
